The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
Cholinergic synapses are ubiquitous in the human central nervous system. Their high
density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic …
density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic …
Rhinitis 2020: a practice parameter update
MS Dykewicz, DV Wallace, DJ Amrol… - Journal of Allergy and …, 2020 - Elsevier
This comprehensive practice parameter for allergic rhinitis (AR) and nonallergic rhinitis
(NAR) provides updated guidance on diagnosis, assessment, selection of monotherapy and …
(NAR) provides updated guidance on diagnosis, assessment, selection of monotherapy and …
Urinary incontinence in women: a review
ES Lukacz, Y Santiago-Lastra, ME Albo, L Brubaker - Jama, 2017 - jamanetwork.com
Importance Urinary incontinence, the involuntary loss of urine, is a common health condition
that may decrease quality of life. Ten to twenty percent of women and up to 77% of women …
that may decrease quality of life. Ten to twenty percent of women and up to 77% of women …
Implementation of subjective cognitive decline criteria in research studies
Introduction Subjective cognitive decline (SCD) manifesting before clinical impairment could
serve as a target population for early intervention trials in Alzheimer's disease (AD). A …
serve as a target population for early intervention trials in Alzheimer's disease (AD). A …
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm …
S Gauthier, HH Feldman, LS Schneider, GK Wilcock… - The Lancet, 2016 - thelancet.com
Background Leuco-methylthioninium bis (hydromethanesulfonate; LMTM), a stable reduced
form of the methylthioninium moiety, acts as a selective inhibitor of tau protein aggregation …
form of the methylthioninium moiety, acts as a selective inhibitor of tau protein aggregation …
EAU guidelines on assessment and nonsurgical management of urinary incontinence
AK Nambiar, R Bosch, F Cruz, GE Lemack… - European urology, 2018 - Elsevier
Abstract Context The European Association of Urology guidelines on urinary incontinence
(UI) have been updated in cyclical fashion with successive major chapters being revised …
(UI) have been updated in cyclical fashion with successive major chapters being revised …
[HTML][HTML] Promoting successful cognitive aging: a ten-year update
TJ Krivanek, SA Gale, BM McFeeley… - Journal of …, 2021 - content.iospress.com
A decade has passed since we published a comprehensive review in this journal
addressing the topic of promoting successful cognitive aging, making this a good time to …
addressing the topic of promoting successful cognitive aging, making this a good time to …
Anticholinergic drugs and risk of dementia: case-control study
K Richardson, C Fox, I Maidment, N Steel, YK Loke… - bmj, 2018 - bmj.com
Objectives To estimate the association between the duration and level of exposure to
different classes of anticholinergic drugs and subsequent incident dementia. Design Case …
different classes of anticholinergic drugs and subsequent incident dementia. Design Case …
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
MW Weiner, DP Veitch, PS Aisen, LA Beckett… - Alzheimer's & …, 2017 - Elsevier
Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued
development and standardization of methodologies for biomarkers and has provided an …
development and standardization of methodologies for biomarkers and has provided an …
[HTML][HTML] Neurogenic bladder: epidemiology, diagnosis, and management
JN Panicker - Seminars in neurology, 2020 - thieme-connect.com
Lower urinary tract dysfunction is a common sequel of neurological disease resulting in
symptoms that significantly impacts quality of life. The site of the neurological lesion and its …
symptoms that significantly impacts quality of life. The site of the neurological lesion and its …